Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410277 · ClinicalTrials.gov registry record · NA
Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)
A NA study of Diabetes Mellitus, Type 1, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT03410277: Completed NA study of Diabetes Mellitus, Type 1, sponsored by University of Minnesota.
NCT03410277 is a NA study of Diabetes Mellitus, Type 1 that has completed, run by University of Minnesota. The registered enrollment target is 47 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03410277, a NA study of Diabetes Mellitus, Type 1, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will explore the cerebral mechanisms of impaired awareness of hypoglycemia (IAH) in type 1 diabetics following exposure to experimental recurrent hypoglycemia (HG). To induce IAH, patients with T1D identified to have normal awareness of hypoglycemia (NAH) will undergo three 2-hour long hypoglycemic clamps. Neurochemical profiles will be measured by high field MRS before and after induction of IAH. Subject glycemic variability for 2 weeks and activity/sleep for 1 week before each study will be monitored as all factors have been shown to alter responses to HG.
Primary Outcome
The difference in neurochemical response (GABA, glutamate, and glucose) to HG during the first clamp study compared to the neurochemical response to HG after the induction of IAH as determined by the last clamp.
Conditions Studied
Interventions
- OTHER Experimental hypoglycemia
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2024-03-31 |
| Phase | NA |
What the finished NCT03410277 record still lists
NCT03410277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Experimental hypoglycemia is the first listed.
NCT03410277 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03410277 about?
NCT03410277 is a clinical study titled "Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)". This study will explore the cerebral mechanisms of impaired awareness of hypoglycemia (IAH) in type 1 diabetics following exposure to experimental recurrent hypoglycemia (HG). To induce IAH, patients with T1D identified to have normal awareness of hypoglycemia (NAH) will undergo three 2-hour long hy...
What is the current status of trial NCT03410277?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2018-05-24. Estimated completion is 2024-03-31.
What conditions does trial NCT03410277 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03410277?
The interventions under investigation include: Experimental hypoglycemia (OTHER).
Who is sponsoring clinical trial NCT03410277?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03410277 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03410277's enrollment target sits among peer trials
47 79th of 118 higher than 40 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
RECRUITING · NA
-
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
RECRUITING · NA
-
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI